Therapeutic Launch Forecast
Quarterly demand forecast for one drug or device, across three geographies.
The Therapeutic Launch Forecast delivers a quarterly forward demand curve for one drug or device through approval and launch, computed across one indication and three geographies. The forecast joins clinical-literature trajectory, prescribing-pattern signal where available, patient-community pulse from disease-specific forums and Reddit, and emerging risk signals from regulator filings and adverse-event surveillance.
The deliverable is a quarterly per-indication report with the demand curve, the patient-community pulse, the literature trajectory with quarter-over-quarter delta, and the named risk signals. Base scope is one indication and three geographies; additional geographies route through scope notes.
Built for pharma brand and medical-comms teams running pre-launch and launch-window programs.
What demand will my drug or device face — and is the conversation bending toward us, quarter over quarter?
What buyers actually ask.
What demand will my drug or device face — and is the conversation bending toward us, quarter over quarter?
The Therapeutic Launch Forecast answers both. The forward demand curve is the quantified read; the patient-community pulse and the QoQ literature trajectory are the conversation read. Each report names what is changing this quarter and which signals support or counter the launch thesis.
How is the forward demand curve computed?
Search-demand telemetry in the indication area, prescribing-pattern public data where available (ICES, OpenPrescribing, comparable public series), clinical-trial enrollment trajectories, and the patient-community pulse are joined into a forward curve. The methodology is named per geography and the assumption set is explicit.
Why three geographies as the base?
Most launch motions span the US plus two other major markets at minimum. Three is the smallest comparative scope where geography-specific divergence is meaningfully informative; four-plus is custom scope.
What does "patient-community pulse" actually capture?
Reddit subreddits for the disease area, condition-specific patient forums, the relevant Twitter/X conversation, and the comment threads on patient-advocacy organizations. The pulse is sentiment scored at the community level plus theme clustering — what patients are asking, hoping, fearing.
How is risk signal surfaced?
FDA adverse-event surveillance (FAERS), EMA pharmacovigilance feeds where public, and the patient-community surfaces themselves — patients post adverse experiences in real time. The report names emerging risks and assesses confidence per signal.
Can I cover multiple indications?
Each Therapeutic Launch Forecast covers one indication at the base SKU. Multiple indications scope as separate orders or as a custom commission with shared methodology so the reads are directly comparable.
How fast is the first report?
First report within ten to fourteen business days of intake confirmation. Subsequent reports refresh quarterly. Subscription billing runs in advance per cycle.
The deliverable, in detail.
- Quarterly forward demand curve through approval and launch for the named indication across three geographies.
- One indication and up to three geographies at the base scope; additional geographies routed through scope notes.
- Patient community pulse with sentiment scoring, theme clustering, and emerging risk signals.
- Clinical literature trajectory with quarter-over-quarter delta analysis and named shift drivers.
How the report is built.
The Therapeutic Launch Forecast scopes one indication and three geographies at intake. The literature pull runs against PubMed, ClinicalTrials.gov, EU Clinical Trials Register, and publisher-side bibliographic data; clinical-literature trajectory is computed at the indication-and-geography level over the time window.
Prescribing and utilization data are pulled from public series where the geography supports them — ICES (Ontario), OpenPrescribing (England), CMS Part D and Medicaid SDUD (US), comparable national series elsewhere. Where public data is thin, the methodology pivots toward search-demand and patient-community proxies, which are named explicitly.
Patient-community pulse runs against Reddit subreddits, condition-specific patient forums, Twitter/X conversation, and the comment surfaces of patient-advocacy organizations. Sentiment and theme clustering are computed at the community level; the report names dominant themes and quarter-over-quarter shifts.
Risk signal joins FDA FAERS, EMA pharmacovigilance public surfaces, and adverse-experience patterns from the patient communities. Emerging risks are named with a confidence tag.
A senior analyst with therapeutic-area context reviews the joined dataset before the report is drafted. The Counter-Signal Pass surfaces the strongest reason the launch thesis might fail — competitor pipeline, payer pushback, regulatory uncertainty.
Counter-Signal Pass is included on every report. The full Foragentis methodology is documented in The State of AEO and GEO in 2026.
What this report does NOT do.
Procurement-grade reports scope themselves. The work below is adjacent and important — and is not in this SKU.
The Therapeutic Launch Forecast does not replace medical-affairs or commercial-team primary research. The patient-community pulse is a public-conversation read, not a moderated qualitative panel; both have value and the brief is calibrated for the public-conversation layer.
Prescribing-data depth varies by geography. Some markets publish granular utilization data; others publish almost nothing public. The report names the data depth per geography so the buyer knows the inheritance.
Adverse-event signal from public conversation is a leading indicator and is not adjudicated. We surface theme density and confidence tag accordingly; medical adjudication is a domain-specialist downstream step.
What the engagement costs.
The Counter-Signal Pass — every thesis stress-tested against its strongest opposing case — is included on every report at no extra cost. See the Counter-Signal block on the catalog hub →
Methodology preview on request.
A redacted public sample for this SKU is in production. To preview the methodology now, email forintel@foragentis.com and we will send the methodology one-pager. The published methodology white paper — The State of AEO and GEO in 2026 — covers the underlying analytical framework.
Adjacent reports.
About Foragentis.
Foragentis is an AI research and product company based in Sacramento, California. ForIntel is the business-intelligence research arm — producing custom dossiers across four buyer lanes: Search & AI Visibility, Markets & Locations, Capital & Innovation, and Specialty.
Every claim in a ForIntel report traces to a public source. Findings are re-verified before delivery. The Adversary/Analyst architecture pairs a senior analyst with a counter-signal pass on every thesis. Anything below our statistical thresholds is labeled directional rather than validated.
Methodology is documented in The State of AEO and GEO in 2026 — a 9,900-word, 42-page public study with effect-size statistics across four frontier AI engines.
Ready to commission the report?
Intake takes under five minutes. We confirm scope, timeline, and cost within one business day.